Related references
Note: Only part of the references are listed.Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Steven W. Pipe et al.
LANCET HAEMATOLOGY (2019)
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Guy Young et al.
BLOOD (2019)
Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers
Naoki Kotani et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
Koichiro Yoneyama et al.
CLINICAL PHARMACOKINETICS (2018)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Factor Villa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
Takehisa Kitazawa et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
Midori Shima et al.
BLOOD ADVANCES (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects
Naoki Uchida et al.
BLOOD (2016)
Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis
L. A. Valentino et al.
HAEMOPHILIA (2016)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Midori Shima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prevention of bleeding in hemophilia patients with high-titer inhibitors
Cindy A. Leissinger et al.
EXPERT REVIEW OF HEMATOLOGY (2015)
Definitions in hemophilia: communication from the SSC of the ISTH
V. S. Blanchette et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Miroslav Dostalek et al.
CLINICAL PHARMACOKINETICS (2013)
Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
Zenjiro Sampei et al.
PLOS ONE (2013)
Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review
Massimo Franchini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice
Rong Deng et al.
MABS (2012)
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Martin Bergstrand et al.
AAPS JOURNAL (2011)
AIC model selection and multimodel inference in behavioral ecology: some background, observations, and comparisons
Kenneth P. Burnham et al.
BEHAVIORAL ECOLOGY AND SOCIOBIOLOGY (2011)
Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
Nicolas Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Reduced elimination of IgG antibodies by engineering the variable region
T. Igawa et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Radojka M. Savic et al.
AAPS JOURNAL (2009)
Population pharmacokinetic analysis of varenicline in adult smokers
Patanjali Ravva et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Measurement and Estimation of GFR in Children and Adolescents
George J. Schwartz et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
B. A. Konkle et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Marilyn J. Manco-Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The risk associated with indwelling catheters in children with haemophilia
Rolf Ljung
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Elimination mechanisms of therapeutic monoclonal antibodies
MA Tabrizi et al.
DRUG DISCOVERY TODAY (2006)
Share Paper
